MENU

LCTX Stock Lineage Cell Therapeutics (LCTX, $0.94) Stochastic Oscillator left the overbought zone on June 27, 2025

A.I.dvisor
at Tickeron.com
Loading...
LCTX - Lineage Cell Therapeutics
Stochastic signal
Bearish Trend
Odds of DOWN Trend
Tickeron
Stochastic signal
Price: $0.9352
Daily change: -$0.0291 (-3.02%)
Daily volume: 19.2M
Capitalization: $213.6M
Industry: Biotechnology
This is a signal that LCTX's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position. A.I.dvisor identified 65 similar cases where LCTX's stochastic oscillator exited the overbought zone, and of them led to successful outcomes. Odds of Success:

LCTX's RSI Indicator recovers from overbought zone

The 10-day RSI Indicator for LCTX moved out of overbought territory on June 26, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 instances where the indicator moved out of the overbought zone. In of the 21 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 65 cases where LCTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LCTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

LCTX broke above its upper Bollinger Band on June 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The 10-day moving average for LCTX crossed bullishly above the 50-day moving average on May 20, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 23 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LCTX advanced for three days, in of 210 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 153 cases where LCTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LCTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.702) is normal, around the industry mean (16.326). P/E Ratio (0.000) is within average values for comparable stocks, (58.407). LCTX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.310). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (20.661) is also within normal values, averaging (252.768).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
LCTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, and neurological conditions

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2173 Salk Avenue
Phone
+1 442 287-8990
Employees
75
Web
https://www.lineagecell.com